Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
OVID

OVID - Ovid therapeutics Inc Stock Price, Fair Value and News

$1.54-0.27 (-14.92%)
Market Closed

27/100

OVID

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

27/100

OVID

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.35

Target 3M

$1.56

Target 6M

$1.44

OVID Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OVID Price Action

Last 7 days

-6.1%

Last 30 days

-6.7%

Last 90 days

12.4%

Trailing 12 Months

111.0%

OVID RSI Chart

OVID Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OVID Valuation

Market Cap

109.7M

Price/Earnings (Trailing)

-3.02

Price/Sales (Trailing)

164.82

EV/EBITDA

-2.48

Price/Free Cashflow

-2.89

OVID Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.35

Target 3M

$1.56

Target 6M

$1.44

OVID Fundamentals

OVID Revenue

Revenue (TTM)

566.0K

Rev. Growth (Yr)

-23.7%

Rev. Growth (Qtr)

-97.9%

OVID Earnings

Earnings (TTM)

-36.3M

Earnings Growth (Yr)

13.19%

Earnings Growth (Qtr)

-159.56%

OVID Profitability

EBT Margin

-6418.82%

Return on Equity

-81.28%

Return on Assets

-56.9%

Free Cashflow Yield

-34.63%

OVID Investor Care

Shares Dilution (1Y)

0.29%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024474.0K568.0K632.0K566.0K
20231.1M698.4K296.3K392.0K
2022156.7M104.9M53.2M1.5M
202161.6M110.5M159.4M208.4M
202000012.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Ovid therapeutics Inc

OVID
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
 CEO
 WEBSITEovidrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES40

Ovid therapeutics Inc Frequently Asked Questions

OVID is the stock ticker symbol of Ovid therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Ovid therapeutics Inc is 109.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check OVID's fair value in chart for subscribers.

The fair value guage provides a quick view whether OVID is over valued or under valued. Whether Ovid therapeutics Inc is cheap or expensive depends on the assumptions which impact Ovid therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OVID.

As of Wed Jan 28 2026, OVID's PE ratio (Price to Earnings) is -3.02 and Price to Sales (PS) ratio is 164.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OVID PE ratio will change depending on the future growth rate expectations of investors.